Here, we show that the synergistic effects observed for the combination of BRD9 targeting and IMiDs against MM are in part mediated by Ikaros proteins, CRBN, and MYC and represent a novel potential approach for the treatment of MM. The gene discussed is CRBN; the disease is Miyoshi myopathy.